

Romano Danesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4509314/publications.pdf>

Version: 2024-02-01

422
papers

14,385
citations

19657

61
h-index

38395

95
g-index

431
all docs

431
docs citations

431
times ranked

18436
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. <i>Journal of Medical Virology</i> , 2022, 94, 491-498.	5.0	17
2	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	1.7	1
3	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103572.	4.4	12
4	Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. <i>Pharmacogenomics</i> , 2022, 23, 119-134.	1.3	1
5	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103602.	4.4	5
6	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	4.4	26
7	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
8	Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. <i>ESMO Open</i> , 2022, 7, 100381.	4.5	1
9	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. <i>ESMO Open</i> , 2022, 7, 100404.	4.5	65
10	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	3.7	15
11	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
12	Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. <i>Clinical Lung Cancer</i> , 2022, 23, 510-521.	2.6	2
13	Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. <i>Pharmacological Research</i> , 2022, 181, 106290.	7.1	4
14	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241.	7.1	23
15	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
16	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188463.	7.4	16
17	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	3.9	32
18	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Pharmacogenomics Journal</i> , 2021, 21, 233-242.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. <i>Cancers</i> , 2021, 13, 771.	3.7	26
20	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	4.5	19
21	Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 370.	4.4	12
22	Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples. <i>Separations</i> , 2021, 8, 63.	2.4	2
23	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. <i>Pharmacological Research</i> , 2021, 167, 105537.	7.1	12
24	Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. <i>Cancers</i> , 2021, 13, 2445.	3.7	4
25	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	4.5	13
26	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM��SIAPEC-IAP��SIBioC��SIC��SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164.	4.5	69
27	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	4.5	20
28	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	7.1	13
29	Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103366.	4.4	7
30	Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 927-935.	7.5	3
31	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3738.	3.7	7
32	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	3.1	4
33	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? �� Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. <i>Clinica Chimica Acta</i> , 2021, 520, 168-171.	1.1	20
34	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	4.4	40
35	Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e048141.	1.9	2
36	Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. <i>ESMO Open</i> , 2021, 6, 100231.	4.5	28

#	ARTICLE	IF	CITATIONS
37	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. UNIPA Springer Series, 2021, , 411-416.	0.1	0
38	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical Lung Cancer, 2020, 21, 232-237.	2.6	24
39	Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919.	4.5	32
40	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2020, 154, 103066.	4.4	7
41	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. Open Forum Infectious Diseases, 2020, 7, ofaa563.	0.9	48
42	KRAS inhibition in non��small cell lung cancer: Past failures, new findings and upcoming challenges. European Journal of Cancer, 2020, 137, 57-68.	2.8	30
43	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and��managing kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
44	CYP17A1 polymorphism c.-362T��C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. Cancer Chemotherapy and Pharmacology, 2020, 86, 527-533.	2.3	9
45	erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020, 5, e000724.	4.5	22
46	1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients. Annals of Oncology, 2020, 31, S1093.	1.2	0
47	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 87-96.	3.3	5
48	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treatment Reviews, 2020, 84, 101966.	7.7	44
49	A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2020, 182, 113132.	2.8	12
50	Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?. Pharmacological Research, 2020, 156, 104786.	7.1	21
51	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 593831.	2.8	25
52	A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 48-48.	1.6	0
53	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.1	0
54	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	4.1	62

#	ARTICLE	IF	CITATIONS
55	Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 57-62.	2.5	71
56	Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients. <i>Annals of Oncology</i> , 2019, 30, v26.	1.2	0
57	Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA. <i>Annals of Oncology</i> , 2019, 30, v643.	1.2	0
58	Circulating biomarkers of response to immunotherapy in cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1247-1249.	1.3	0
59	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	4.4	7
60	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019, 21, 1610-1611.	1.2	8
61	Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1219-1227.	2.3	6
62	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019, 74, 21-28.	7.7	31
63	Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e331-e333.	2.3	5
64	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 483-494.	2.5	28
65	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	7.7	159
66	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	2.5	32
67	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. <i>BMC Cancer</i> , 2019, 19, 410.	2.6	16
68	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , 2019, 131, 78-85.	2.0	42
69	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	2.0	35
70	Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1255-1257.	1.3	7
71	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. <i>Frontiers in Oncology</i> , 2019, 9, 1417.	2.8	12
72	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 254-255.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019, 37, 3-14.	1.7	59
74	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	7.1	280
75	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019, 20, 49-68.	1.3	23
76	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, e14054-e14054.	1.6	0
77	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	6.4	190
78	Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 745-754.	2.3	18
79	Clinical pharmacology of intravitreal anti-VEGF drugs. <i>Eye</i> , 2018, 32, 1010-1020.	2.1	143
80	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. <i>Stem Cells Translational Medicine</i> , 2018, 7, 305-314.	3.3	65
81	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , 2018, 36, 633-640.	3.2	32
82	Individualized dosing with axitinib: rationale and practical guidance. <i>Future Oncology</i> , 2018, 14, 861-875.	2.4	15
83	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	4.4	8
84	Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. <i>Molecular Neurobiology</i> , 2018, 55, 1396-1404.	4.0	7
85	Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. <i>Lung Cancer</i> , 2018, 115, 21-27.	2.0	87
86	Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 306-315.	3.7	56
87	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-687. <i>European Urology</i> , 2018, 73, e11-e12.	1.9	0
88	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 602-609.	2.0	14
89	Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. <i>Annals of Oncology</i> , 2018, 29, viii27.	1.2	0
90	Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. <i>Annals of Oncology</i> , 2018, 29, viii46.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Into Imaging, 2018, 9, 915-924.	3.4	47
92	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. British Journal of Cancer, 2018, 119, 1252-1258.	6.4	39
93	Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. Annals of Oncology, 2018, 29, v102.	1.2	4
94	Genome Wide Association Studies (GWAS). , 2018, , .		0
95	Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer. Annals of Oncology, 2018, 29, viii53.	1.2	0
96	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics, 2018, 19, 727-740.	1.3	20
97	Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. Annals of Oncology, 2018, 29, 1893-1894.	1.2	4
98	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respiratory Research, 2018, 19, 154.	3.6	33
99	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. Journal of Clinical Oncology, 2018, 36, 12007-12007.	1.6	13
100	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget, 2018, 9, 6630-6643.	1.8	42
101	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	1.8	25
102	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. Translational Cancer Research, 2018, 8, S16-S22.	1.0	0
103	Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World. Clinical Cancer Drugs, 2018, 4, .	0.3	0
104	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. Journal of Clinical Oncology, 2018, 36, 210-210.	1.6	0
105	Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinix in pancreas cancer.. Journal of Clinical Oncology, 2018, 36, e24128-e24128.	1.6	0
106	Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.. Journal of Clinical Oncology, 2018, 36, 12037-12037.	1.6	1
107	PLASMA/SALIVA AND GENOTYPIC/PHENOTYPIC DIFFERENCES OF NICOTINE METABOLITE RATIO.. , 2018, , .		0
108	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 2017, 55, 71-82.	7.7	56

#	ARTICLE	IF	CITATIONS
109	Determinants of bone specific metastasis in prostate cancer. Critical Reviews in Oncology/Hematology, 2017, 112, 59-66.	4.4	18
110	The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs, 2017, 77, 671-677.	10.9	106
111	Simultaneous, but not consecutive combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro. European Journal of Cancer, 2017, 72, S68.	2.8	0
112	Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2017, 57, 28-35.	7.7	15
113	Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 319-334.	4.7	26
114	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer, 2017, 18, 692-697.	2.6	49
115	Nicotine Metabolite Ratio in Smokers: A Real World Experience. Clinical Therapeutics, 2017, 39, e87.	2.5	0
116	Should <i>CYP2D6</i> be genotyped when treating with tamoxifen?. Pharmacogenomics, 2017, 18, 755-756.	1.3	1
117	Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment. EPMA Journal, 2017, 8, 69-73.	6.1	7
118	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2017, 79, 767-773.	2.3	12
119	Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Scientific Reports, 2017, 7, 7931.	3.3	66
120	PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy. Radiotherapy and Oncology, 2017, 123, S329-S330.	0.6	0
121	Pharmacogenetics and Personalized Medicine. , 2017, , 149-168.		1
122	Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?. Annals of Oncology, 2017, 28, 183.	1.2	12
123	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology, 2017, 71, 680-687.	1.9	213
124	Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Annals of Oncology, 2017, 28, vi48.	1.2	1
125	Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. Current Pharmaceutical Design, 2017, 23, 2028-2034.	1.9	7
126	Dihydropyrimidine dehydrogenase (DPD) deficiency: how to translate it in clinical practice?. Annals of Oncology, 2017, 28, vi12-vi13.	1.2	0

#	ARTICLE	IF	CITATIONS
127	Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. <i>Frontiers in Pharmacology</i> , 2017, 8, 523.	3.5	9
128	Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. <i>International Journal of Molecular Sciences</i> , 2017, 18, 104.	4.1	31
129	Simultaneous, But Not Consecutive, Combination With Folate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. <i>Oncology Research</i> , 2017, 25, 1129-1140.	1.5	8
130	Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, vi47.	1.2	0
131	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	2.8	45
132	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	1.8	28
133	Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , 2017, 8, 86056-86065.	1.8	13
134	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
135	Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 13611-13619.	1.8	81
136	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15794-e15794.	1.6	1
137	Characteristics of smokers according to their Nicotine Metabolite Ratio, preliminary results from a real-life experience. , 2017, , .		0
138	Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015. <i>Ecancermedalscience</i> , 2016, 10, 611.	1.1	9
139	<i>Topoisomerase 1</i> Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016, 91, 283-288.	1.9	5
140	2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S57.	1.1	2
141	Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 839-848.	1.9	57
142	Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?. <i>Pharmacological Research</i> , 2016, 107, 398-406.	7.1	32
143	Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 208-213.	2.8	7
144	Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , 2016, 8, 1151-1167.	2.1	8

#	ARTICLE	IF	CITATIONS
145	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1419-1432.	3.3	46
146	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Investigational New Drugs, 2016, 34, 760-770.	2.6	29
147	Should <i>CYP2D6</i> be genotyped when treating with tamoxifen?. Pharmacogenomics, 2016, 17, 1967-1969.	1.3	7
148	The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 109-130.	0.1	0
149	AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer. Annals of Oncology, 2016, 27, vi248.	1.2	1
150	Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. Journal of Theoretical Biology, 2016, 389, 263-273.	1.7	31
151	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta -analysis of published trials. Critical Reviews in Oncology/Hematology, 2016, 101, 12-20.	4.4	37
152	Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. Pharmacogenomics, 2016, 17, 5-9.	1.3	12
153	Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacological Research, 2016, 103, 149-157.	7.1	47
154	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. Journal of Clinical Oncology, 2016, 34, e20526-e20526.	1.6	0
155	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	1.4	0
156	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA Journal, 2015, 6, 17.	6.1	12
157	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	2.6	10
158	Real-time PCR and Droplet Digital PCR: two techniques for detection of the <i>JAK2</i> V617F mutation in Philadelphia-negative chronic myeloproliferative neoplasms. International Journal of Laboratory Hematology, 2015, 37, 766-773.	1.3	30
159	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalscience, 2015, 9, 553.	1.1	0
160	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. International Journal of Molecular Sciences, 2015, 16, 22811-22829.	4.1	33
161	Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. European Urology, 2015, 67, 680-681.	1.9	3
162	Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1253-1267.	3.3	2

#	ARTICLE	IF	CITATIONS
163	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 165-178.	4.4	26
164	EPMA position paper in cancer: current overview and future perspectives. <i>EPMA Journal</i> , 2015, 6, 9.	6.1	86
165	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	4.1	43
166	Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". <i>Tumor Biology</i> , 2015, 36, 7397-7398.	1.8	1
167	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	3.1	16
168	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	2.4	17
169	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015, 7, 757-765.	2.1	22
170	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3532-3532.	1.6	2
171	Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. <i>Oncotarget</i> , 2015, 6, 28743-28754.	1.8	21
172	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 584-97.	2.8	52
173	Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4838-4838.	1.4	0
174	Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. <i>Anticancer Research</i> , 2015, 35, 269-71.	1.1	4
175	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014, 15, 1985-1999.	1.3	16
176	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. <i>Pharmacogenomics Journal</i> , 2014, 14, 328-335.	2.0	45
177	Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets. <i>Oncologist</i> , 2014, 19, 344-345.	3.7	9
178	Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. <i>Cancer</i> , 2014, 120, 3923-3931.	4.1	33
179	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. <i>Molecular and Cellular Endocrinology</i> , 2014, 393, 56-64.	3.2	21
180	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	3.6	27

#	ARTICLE	IF	CITATIONS
181	Different Recommendations for Daptomycin Dosing Over Time in Patients With Severe Infections. <i>Clinical Infectious Diseases</i> , 2014, 58, 1788-1789.	5.8	13
182	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E572-E581.	3.6	46
183	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468.	3.1	17
184	Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. <i>Surgery</i> , 2014, 156, 1167-1176.	1.9	17
185	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 446-456.	7.4	15
186	Breast Lymphomas Around Breast Implants. <i>Annals of Surgery</i> , 2014, 259, e4.	4.2	0
187	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11056-11056.	1.6	0
188	Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22075-e22075.	1.6	0
189	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. <i>Endocrine Practice</i> , 2013, 19, 1043-1049.	2.1	16
190	DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. <i>Pharmacogenomics</i> , 2013, 14, 1255-1272.	1.3	126
191	Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 250-255.	2.5	47
192	Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid. <i>Clinical Pharmacokinetics</i> , 2013, 52, 511-542.	3.5	40
193	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1465-E1473.	3.6	33
194	Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 784-792.	7.7	25
195	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 473-475.	3.4	0
196	Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1137-1141.	2.8	24
197	P.2.d.040 Psychiatric patients carrying the CYP2C9*2 allele require lower doses of valproic acid to achieve target plasma levels. <i>European Neuropsychopharmacology</i> , 2013, 23, S387.	0.7	0
198	The pharmacological bases of the antiangiogenic activity of paclitaxel. <i>Angiogenesis</i> , 2013, 16, 481-492.	7.2	149

#	ARTICLE	IF	CITATIONS
199	Synergistic interaction between <sc>PPAR</sc> ligands and salbutamol on human bronchial smooth muscle cell proliferation. British Journal of Pharmacology, 2013, 168, 266-275.	5.4	10
200	Histone lysine demethylases in breast cancer. Critical Reviews in Oncology/Hematology, 2013, 86, 97-103.	4.4	53
201	<i>VEGF-A</i> polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics, 2013, 14, 623-630.	1.3	29
202	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncology Letters, 2013, 6, 1487-1491.	1.8	21
203	Embryonic stem cell pathways and chemotherapy response: an unexplored route. Annals of Oncology, 2013, 24, 558-559.	1.2	0
204	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British Journal of Cancer, 2013, 109, 957-964.	6.4	41
205	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.. Journal of Clinical Oncology, 2013, 31, 382-382.	1.6	1
206	Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR.. Journal of Clinical Oncology, 2013, 31, e22056-e22056.	1.6	0
207	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.. Journal of Clinical Oncology, 2013, 31, 11058-11058.	1.6	0
208	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial.. Journal of Clinical Oncology, 2013, 31, 3603-3603.	1.6	0
209	Abstract P1-08-31: Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy. , 2013, , .		0
210	An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. Biomarkers in Medicine, 2012, 6, 201-209.	1.4	30
211	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf Letter. Clinical Cancer Research, 2012, 18, 4473-4473.	7.0	0
212	Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1735-1746.	4.1	84
213	Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity. Current Topics in Medicinal Chemistry, 2012, 12, 1713-1719.	2.1	15
214	Time-Dependent Pharmacokinetics of 5-Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer. Journal of Clinical Pharmacology, 2012, 52, 361-369.	2.0	10
215	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer and Metastasis Reviews, 2012, 31, 753-761.	5.9	148
216	Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treatment Reviews, 2012, 38, 442-450.	7.7	28

#	ARTICLE	IF	CITATIONS
217	The emerging role of histone lysine demethylases in prostate cancer. <i>Molecular Cancer</i> , 2012, 11, 52.	19.2	72
218	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	3.4	13
219	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371.	1.2	7
220	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	1.2	40
221	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. <i>Pharmacogenomics</i> , 2012, 13, 1037-1053.	1.3	27
222	Polycomb genes and cancer: Time for clinical application?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 184-193.	4.4	74
223	Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2012, 41, e24-e30.	1.6	14
224	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E528-E536.	3.6	49
225	Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1. <i>Neoplasia</i> , 2012, 14, 833-IN11.	5.3	36
226	The rs2071559 AA<i>VEGFR-2</i>Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	2.1	13
227	First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. <i>Investigational New Drugs</i> , 2012, 30, 1725-1730.	2.6	33
228	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012, 15, 275-286.	7.2	61
229	Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 103-122.	4.4	154
230	Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13057-e13057.	1.6	1
231	Abstract 4375: Sunitinib alone and in combination with SN-38 is active against anaplastic thyroid cancer. , 2012, , .		0
232	Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab. , 2012, , .		0
233	Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 721-727.	1.5	22
234	Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo. <i>Neoplasia</i> , 2011, 13, 217-IN3.	5.3	31

#	ARTICLE	IF	CITATIONS
235	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 1015-1021.	0.9	10
236	Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. <i>Lung Cancer</i> , 2011, 74, 197-205.	2.0	22
237	Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. <i>Drug Resistance Updates</i> , 2011, 14, 280-296.	14.4	113
238	Pharmacogenomics and cancer stem cells: a changing landscape?. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 487-494.	8.7	23
239	PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele. <i>European Journal of Cancer</i> , 2011, 47, S16-S17.	2.8	2
240	Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity. <i>Current Drug Metabolism</i> , 2011, 12, 932-943.	1.2	47
241	Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 768-773.	1.1	14
242	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2011, 6, 395-396.	1.1	44
243	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269.	6.4	85
244	Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. <i>Biochemical Pharmacology</i> , 2011, 81, 1309-1316.	4.4	26
245	ALK-1â€“Negative Anaplastic Large Cell Lymphoma Associated With Breast Implants: A New Clinical Entity. <i>Clinical Breast Cancer</i> , 2011, 11, 283-296.	2.4	72
246	Promoting predictive, preventive and personalised medicine: European event of global importance. <i>EPMA Journal</i> , 2011, 2, 131-136.	6.1	9
247	Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. <i>Molecular Cancer</i> , 2011, 10, 40.	19.2	150
248	BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. <i>International Journal of Cancer</i> , 2011, 128, 1946-1954.	5.1	73
249	Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1303-1313.	2.4	10
250	Estrogen Receptor \pm and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E368-E372.	3.6	28
251	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E288-E296.	3.6	71
252	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3487-3488.	1.6	14

#	ARTICLE	IF	CITATIONS
253	Case Report of a Successful Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Bacteremia and MRSA/Vancomycin-Resistant <i>Enterococcus faecium</i> Cholecystitis by Daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2458-2459.	3.2	25
254	Impact of <i>ABCG2</i> polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011, 12, 159-170.	1.3	63
255	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2011, 96, 937-942.	3.5	62
256	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	1.6	12
257	A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 200-205.	2.0	32
258	Expression of nucleoside transporters, deoxycytidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 679-686.	2.3	56
259	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 547-558.	2.3	18
260	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. <i>EPMA Journal</i> , 2010, 1, 495-502.	6.1	22
261	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010, 10, 511.	2.6	47
262	METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 986-988.	2.6	27
263	Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells. <i>Chemotherapy</i> , 2010, 56, 303-312.	1.6	21
264	Administration Interval and Daptomycin Toxicity: A Case Report of Rhabdomyolysis. <i>Journal of Chemotherapy</i> , 2010, 22, 434-435.	1.5	9
265	Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing. <i>Journal of Clinical Oncology</i> , 2010, 28, e221-e222.	1.6	21
266	Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010, 29, 419-426.	1.1	13
267	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010, 10, 180-190.	2.0	22
268	Periorbital necrotising fasciitis. <i>British Journal of Ophthalmology</i> , 2010, 94, 1577-1585.	3.9	97
269	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. <i>Cancer Research</i> , 2010, 70, 4528-4538.	0.9	409
270	Overexpression and Functional Relevance of Somatostatin Receptor-1, -2, and -5 in Endometrium and Endometriotic Lesions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5315-5319.	3.6	17

#	ARTICLE	IF	CITATIONS
271	Pharmacological Issues of Linezolid. Clinical Pharmacokinetics, 2010, 49, 439-447.	3.5	75
272	12 Pharmacogenetics of drug transporters. European Journal of Cancer, Supplement, 2010, 8, 14.	2.2	0
273	Association of Polymorphisms in <i>AKT1</i> and <i>EGFR</i> with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib. Molecular Cancer Therapeutics, 2010, 9, 581-593.	4.1	67
274	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Journal of Experimental and Clinical Cancer Research, 2010, 29, 95.	8.6	94
275	Metronomic Chemotherapy for Metastatic Prostate Cancer. Drugs and Aging, 2010, 27, 689-696.	2.7	21
276	Pharmacogenetics of Angiogenesis. , 2010, , 233-242.		0
277	Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. , 2010, , .		0
278	Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue. Journal of Endometriosis, 2009, 1, 94-101.	1.0	2
279	Cancer stem cell epigenetics and chemoresistance. Epigenomics, 2009, 1, 63-79.	2.1	64
280	Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics, 2009, 10, 69-80.	1.3	41
281	Discordant somatic and germline <i>VEGF-A</i> genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics, 2009, 10, 1225-1229.	1.3	7
282	Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 1964-1973.	4.1	39
283	Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer. Clinical Cancer Research, 2009, 15, 4954-4962.	7.0	85
284	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology, 2009, 619, 8-14.	3.5	35
285	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Critical Reviews in Oncology/Hematology, 2009, 72, 21-44.	4.4	24
286	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. British Journal of Clinical Pharmacology, 2009, 67, 132-134.	2.4	9
287	Pharmacogenomics in non-small-cell lung cancer chemotherapy. Advanced Drug Delivery Reviews, 2009, 61, 408-417.	13.7	30
288	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Molecular Cancer Therapeutics, 2009, 8, 2496-2508.	4.1	157

#	ARTICLE	IF	CITATIONS
289	OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib. European Journal of Cancer, Supplement, 2009, 7, 9.	2.2	0
290	<i>ABCB1</i> polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics, 2009, 10, 1267-1276.	1.3	53
291	TOP2A mRNA expression in HER2 negative breast cancer.. , 2009, , .		2
292	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Laboratory Investigation, 2008, 88, 773-784.	3.7	34
293	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. British Journal of Cancer, 2008, 98, 1619-1629.	6.4	85
294	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU International, 2008, 102, 617-621.	2.5	60
295	Serotonin syndrome and the T ₁₀₂ C polymorphism of the 5-HT _{2A} receptor: a case report. Bipolar Disorders, 2008, 10, 655-656.	1.9	7
296	Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?. European Urology, 2008, 54, 938-941.	1.9	5
297	Pharmacogenetics in oncology. European Journal of Cancer, Supplement, 2008, 6, 74-78.	2.2	1
298	Pharmacogenetics in oncology. European Journal of Cancer, Supplement, 2008, 6, 139.	2.2	1
299	Association of the <i>CYP1B1</i> *3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics, 2008, 7, 19-26.	4.1	79
300	Effect of <i>SLCO1B3</i> Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. Clinical Cancer Research, 2008, 14, 3312-3318.	7.0	175
301	Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells. Molecular Pharmacology, 2008, 73, 1290-1300.	2.3	149
302	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 98, 1312-1319.	6.4	63
303	Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 720-725.	1.1	60
304	5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer. Clinical Cancer Research, 2008, 14, 2749-2755.	7.0	52
305	Correlation of <i>CDA</i> , <i>ERCC1</i> , and <i>XPB</i> Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2008, 14, 1797-1803.	7.0	193
306	Pharmacogenetics of Antiangiogenic Therapy. , 2008, , 477-486.		0

#	ARTICLE	IF	CITATIONS
307	Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. <i>Pharmacogenomics</i> , 2007, 8, 49-66.	1.3	52
308	The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S27-S30.	1.1	5
309	Suicide Gene Therapy With the Yeast Fusion Gene Cytosine Deaminase/Uracil Phosphoribosyltransferase Is Not Enough for Pancreatic Cancer. <i>Pancreas</i> , 2007, 35, 224-231.	1.1	9
310	Linezolid Cerebrospinal Fluid Concentration in Central Nervous System Infection. <i>Journal of Chemotherapy</i> , 2007, 19, 90-93.	1.5	20
311	Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate Cancer. <i>Urology</i> , 2007, 70, 217-220.	1.0	30
312	Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. <i>Pharmacological Research</i> , 2007, 55, 343-349.	7.1	28
313	D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2007, 2, S398-S399.	1.1	0
314	CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2224-2231.	3.3	89
315	In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. <i>European Journal of Clinical Investigation</i> , 2007, 37, 700-708.	3.4	28
316	242: Pharmacogenetics Determinants of Anticancer Activity of Intravesical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder. <i>Journal of Urology</i> , 2007, 177, 81-81.	0.4	0
317	Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration. <i>Journal of Clinical Oncology</i> , 2007, 25, 14145-14145.	1.6	0
318	610 POSTER Synergistic cytotoxicity, inhibition of Akt and c-Kit phosphorylation and modulation of gene expression by sorafenib and gemcitabine in human pancreatic cancer cells. <i>European Journal of Cancer</i> , Supplement, 2006, 4, 184.	2.2	0
319	Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 809-816.	1.5	29
320	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297.	6.4	43
321	A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 384-395.	4.7	63
322	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 585-593.	2.3	13
323	In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. <i>European Journal of Pharmacology</i> , 2006, 549, 27-34.	3.5	17
324	Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition. <i>ChemMedChem</i> , 2006, 1, 218-224.	3.2	5

#	ARTICLE	IF	CITATIONS
325	Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. <i>Cancer Research</i> , 2006, 66, 3928-3935.	0.9	307
326	In vitro studies on gemcitabine combinations with other antiproliferatives. <i>Annals of Oncology</i> , 2006, 17, v17-v19.	1.2	10
327	Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1387-1395.	4.1	83
328	Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7099-7107.	7.0	52
329	Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients. <i>Current Clinical Pharmacology</i> , 2006, 1, 311-323.	0.6	22
330	Pharmacogenetics in Oncology. , 2006, , 129-153.		0
331	Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 362-368.	2.0	24
332	Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. <i>British Journal of Cancer</i> , 2005, 93, 319-330.	6.4	69
333	5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. <i>Toxicology and Applied Pharmacology</i> , 2005, 203, 106-113.	2.8	6
334	Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. <i>British Journal of Cancer</i> , 2005, 92, 681-689.	6.4	30
335	Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2005, 93, 35-40.	6.4	63
336	Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2005, 68, 110-118.	2.3	176
337	Importance of Preclinical Investigations of the Integration of Capecitabine into Polychemotherapy Regimens. <i>Clinical Colorectal Cancer</i> , 2005, 4, 344.	2.3	0
338	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	1.6	31
339	A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed. <i>Clinical Cancer Research</i> , 2004, 10, 1657-1663.	7.0	23
340	Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2004, 10, 2936-2943.	7.0	90
341	Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. <i>European Journal of Pharmacology</i> , 2004, 498, 9-18.	3.5	43
342	Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 854-860.	2.0	107

#	ARTICLE	IF	CITATIONS
343	Biologic Basis of Ovarian Metastasis of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 3, 223-224.	2.3	1
344	Genetic Determinants in the Study of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 260-261.	2.3	0
345	Pharmacogenetics of neoplastic diseases: new trends. <i>Pharmacological Research</i> , 2004, 49, 331-342.	7.1	21
346	Hematologic toxicity of immunosuppressive treatment. <i>Transplantation Proceedings</i> , 2004, 36, 703-704.	0.6	80
347	Teratogenesis and immunosuppressive treatment. <i>Transplantation Proceedings</i> , 2004, 36, 705-707.	0.6	45
348	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. <i>Journal of Clinical Oncology</i> , 2004, 22, 2072-2072.	1.6	9
349	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. <i>Journal of Clinical Oncology</i> , 2004, 22, 2072-2072.	1.6	0
350	Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. <i>European Journal of Pharmacology</i> , 2003, 477, 17-21.	3.5	5
351	Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. <i>Il Farmaco</i> , 2003, 58, 85-89.	0.9	3
352	Ceramide analogues in apoptosis: a new strategy for anticancer drug development. <i>Il Farmaco</i> , 2003, 58, 205-211.	0.9	14
353	Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4405-4408.	2.2	5
354	High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine+epirubicin+paclitaxel in metastatic breast cancer: a dose finding study. <i>Bone Marrow Transplantation</i> , 2003, 31, 275-280.	2.4	6
355	Predicting Survival with Artificial Neural Networks. <i>Clinical Colorectal Cancer</i> , 2003, 2, 245.	2.3	1
356	Impact of Locoregional Approaches to Liver Metastases in Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2003, 3, 45-46.	2.3	0
357	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Pharmacological Reviews</i> , 2003, 55, 57-103.	16.0	65
358	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 71-84.	14.4	207
359	Molecular targeted treatments for fungal infections: the role of drug combinations. <i>Trends in Molecular Medicine</i> , 2003, 9, 269-276.	6.7	10
360	Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 939-945.	3.0	48

#	ARTICLE	IF	CITATIONS
361	Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S115-S122.	1.3	10
362	Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 309-318.	4.1	58
363	Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 919-927.	1.2	48
364	Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4006-4014.	1.6	148
365	Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouacil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 588-593.	2.0	23
366	Irinotecan in 5-Fluorouracil-Resistant Refractory Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2002, 2, 102-103.	2.3	0
367	Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 2002, 41, 431-444.	3.5	168
368	Molecular basis of resistance to azole antifungals. <i>Trends in Molecular Medicine</i> , 2002, 8, 76-81.	6.7	381
369	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouacil: a case report. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 593-595.	1.9	17
370	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 508-518.	2.4	42
371	Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 263-271.	4.7	6
372	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 627-637.	4.7	23
373	Commentary on "The Role of Adjuvant Therapy After Liver Resection for Colorectal Metastases". <i>Clinical Colorectal Cancer</i> , 2001, 1, 167-168.	2.3	0
374	Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3994-4000.	6.4	49
375	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 420-426.	8.7	54
376	Synergistic chemotherapeutic activity of gemcitabine and fluvastatin on pancreas cancer in vitro. <i>Gastroenterology</i> , 2001, 120, A617.	1.3	0
377	Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3456-3462.	1.6	51
378	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. <i>Annals of Oncology</i> , 2001, 12, 1301-1306.	1.2	94

#	ARTICLE	IF	CITATIONS
379	Acetylcholinesterase Blockade Does Not Account for the Adverse Cardiovascular Effects of the Antitumor Drug Irinotecan: A Preclinical Study. <i>Toxicology and Applied Pharmacology</i> , 2001, 177, 149-156.	2.8	8
380	Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 171-179.	2.5	82
381	Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. <i>British Journal of Cancer</i> , 2001, 84, 1535-1543.	6.4	22
382	Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. <i>British Journal of Cancer</i> , 2001, 85, 1425-1431.	6.4	12
383	In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. <i>Molecular Human Reproduction</i> , 2001, 7, 771-777.	2.8	40
384	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000, 11, 821-827.	1.2	26
385	Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. <i>Cytometry</i> , 2000, 42, 254-260.	1.8	28
386	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. <i>Laboratory Investigation</i> , 2000, 80, 1413-1419.	3.7	26
387	Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. <i>Trends in Molecular Medicine</i> , 2000, 6, 475-482.	2.6	22
388	Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. <i>British Journal of Cancer</i> , 2000, 82, 905-912.	6.4	33
389	Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. <i>Cytometry</i> , 2000, 42, 254-260.	1.8	13
390	Variable Correlation Between 6-Mercaptopurine Metabolites in Erythrocytes and Hematologic Toxicity: Implications for Drug Monitoring in Children With Acute Lymphoblastic Leukemia. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 375-382.	2.0	15
391	Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. <i>Clinical Cancer Research</i> , 2000, 6, 3032-7.	7.0	68
392	Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors. <i>Journal of Clinical Oncology</i> , 1999, 17, 3596-3602.	1.6	89
393	Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 133-140.	2.3	11
394	Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 205-212.	2.3	49
395	Pharmacokinetic Optimisation of Treatment Schedules for Anthracyclines and Paclitaxel in Patients with Cancer. <i>Clinical Pharmacokinetics</i> , 1999, 37, 195-211.	3.5	43
396	An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 367.	2.0	68

#	ARTICLE	IF	CITATIONS
397	Ultrastructural and Biochemical Evidence of Apoptosis Induced by a Novel Inhibitor of Protein Geranylgeranylation in Human MIA PaCa-2 Pancreatic Cancer Cells. Ultrastructural Pathology, 1998, 22, 253-261.	0.9	8
398	The Heparan Sulfate Suleparioide Inhibits Rat Corneal Angiogenesis and in vitro Neovascularization. Experimental Eye Research, 1998, 67, 133-142.	2.6	39
399	Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine. Clinical Pharmacokinetics, 1998, 34, 173-180.	3.5	10
400	Periodontal Tissue Disposition of Azithromycin. Journal of Periodontology, 1997, 68, 1206-1209.	3.4	55
401	Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.. Journal of Clinical Oncology, 1997, 15, 2510-2517.	1.6	89
402	Effect of Suramin on Ethanol-Induced Gastric Mucosal Injury: Relationship between Tissue Distribution and Severity of Damage. , 1997, , 129-138.		0
403	Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS) Tj ETQq1 1 0.784314 rgBT / Overlock 10	7.0	75
404	Geranylgeranyl Diphosphate-Based Inhibitors of Post-Translational Geranylgeranylation of Cellular Proteins. Journal of Medicinal Chemistry, 1996, 39, 1352-1356.	6.4	34
405	Effect of suramin on ethanol-induced gastric mucosal injury: Relationship between tissue distribution and severity of damage. Inflammopharmacology, 1996, 4, 331-340.	3.9	0
406	Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. International Journal of Cancer, 1995, 63, 124-129.	5.1	20
407	Specific Labeling of Isoprenylated Proteins: Application to Study Inhibitors of the Post-translational Farnesylation and Geranylgeranylation. Biochemical and Biophysical Research Communications, 1995, 206, 637-643.	2.1	42
408	Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Molecular Pharmacology, 1995, 47, 1106-11.	2.3	43
409	Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation. British Journal of Cancer, 1993, 67, 1209-1216.	6.4	3
410	Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role. Agents and Actions, 1993, 38, 85-90.	0.7	55
411	Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. British Journal of Cancer, 1993, 68, 932-938.	6.4	74
412	Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4-â€²-amino-3-â€²-hydroxy-doxorubicin. Cancer Chemotherapy and Pharmacology, 1992, 29, 261-265.	2.3	8
413	Effect of Suramin on Human Prostate Cancer Cells in Vitro. Journal of Urology, 1991, 145, 393-398.	0.4	74
414	The effect of rhGM-CSF on the proliferation of osteogenic sarcoma cells. American Journal of Hematology, 1991, 37, 84-87.	4.1	6

#	ARTICLE	IF	CITATIONS
415	A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer, 1991, 67, 1509-1513.	4.1	46
416	A pilot study of suramin in the treatment of metastatic renal cell carcinoma. , 1991, 67, 1509.		1
417	Roxithromycin Penetration into Gingiva and Alveolar Bone of Odontoiatric Patients. Chemotherapy, 1990, 36, 332-336.	1.6	13
418	Cardiac toxicity and antitumor activity of 4â€²-deoxy-4â€²-iodo-doxorubicinol. Cancer Chemotherapy and Pharmacology, 1990, 26, 403-408.	2.3	9
419	Suramin in Adrenal Cancer: Modulation of Steroid Hormone Production, Cytotoxicity<i>in Vitro</i>, and Clinical Antitumor Effect*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 497-504.	3.6	86
420	Suramin, a novel antitumor compound. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 893-898.	2.5	55
421	Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers. Arzneimittelforschung, 1988, 38, 129-31.	0.4	0
422	A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. Drugs Under Experimental and Clinical Research, 1988, 14, 39-43.	0.3	5